SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, is proud to introduce a new small-volume ready-to-use (RTU) cartridge for human use to the market. The 1.5 ml sterile cartridge represents a significant expansion of SCHOTT Pharma’s cartriQ portfolio and offers the smallest sterile format to date, which is critical for the stable storage of insulin, GLP-1 drugs, or hormone therapies. The portfolio expansion is in line with SCHOTT Pharma's strategic goal to provide its customers with high-value solutions, further solidifying the company’s leading position. The new 1.5 ml format is ISO-compliant and has been developed with a state-of-the-art siliconisation process as well as the recently introduced diamond-shaped nest design for optimal output, enabling pharmaceutical companies to increase production efficiency, reduce total cost of ownership and accelerate time-to-market for medications.
Transforming pharmaceutical manufacturing
The pharmaceutical industry is continuously evaluating manufacturing processes to achieve higher drug yields using less resources. This has led to a fundamental rethinking of pharmaceutical manufacturing and a shift towards utilising RTU drug containment and delivery systems, which enhance process flexibility and efficiency while maintaining high-quality standards.
Andreas Reisse, CEO of SCHOTT Pharma, states: “For our RTU products, we handle washing, siliconisation, crimping, and sterilisation processes from pharmaceutical manufacturers. This enables them to increase efficiency, reduce total cost of ownership, and accelerate time-to-market for their medications. Our approach creates high-value solutions for our customers and supports our strategy to increase revenue from these offerings.”
SCHOTT Pharma’s standardised nest and tub, along with its pre-washed, and pre-sterilised RTU drug containment and delivery portfolio, provide easy and flexible production scale-up for pharmaceutical manufacturers and Contract Development and Manufacturing Organisations (CDMOs). The new 1.5 ml sterile cartridge format, developed alongside the optimised diamond-shaped nest, enhances efficiency of pharmaceutical filling processes by up to 67% and reduces CO2 emissions by nearly 25% in the supply chain.
Facilitating homecare
SCHOTT Pharma is working closely with leading device manufacturers such as Ypsomed to simplify the self-administration of medications at home, for example for chronic diseases such as diabetes, obesity, or growth hormone deficiency. This trend not only improves the lives of patients but also eases the burden on the healthcare system. The new 1.5 ml sterile cartridge is compatible with a broad range of pen injectors, for example Ypsomed's UnoPen®, providing pharmaceutical companies with a pre-tested system, including device and container.
Innovation and collaboration with trusted partners are key strategic pillars for SCHOTT Pharma, driving progress in pharmaceutical manufacturing while creating efficient, sustainable, and patient-friendly solutions.
More information on RTU cartridges from SCHOTT Pharma: https://www.schott-pharma.com/en/products/pharmaceutical-cartridges/cartriq
